← Back to Clinical Trials
Recruiting NCT06710067

Urine Metabolites in the Diagnosis of Disease

◆ AI Clinical Summary

This study tests a new urine-based test that could help doctors detect colorectal cancer and other digestive system diseases without invasive procedures. Researchers want to see if analyzing urine samples can accurately identify and distinguish between different gastrointestinal conditions.

Key Objective: The potential benefit is a simple, non-invasive urine test that could detect colorectal cancer earlier and more conveniently than current screening methods.

Who to Consider: People with colorectal cancer or those at risk for gastrointestinal diseases who are interested in helping develop a simpler diagnostic tool should consider enrolling.

Trial Parameters

Condition Colorectal Cancer
Sponsor Luventix, Inc.
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,250
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-10-01
Completion 2025-09

Brief Summary

The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases. This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease. The main questions it aims to answer are: 1. Does the platform identify a disease signal within each disease cohort, compared to normal controls? 2. How well does the test perform (e.g. sensitivity and specificity/false-positive rate)?

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years of age at time of enrollment. * Able and willing to provide a one-time urine sample and comply with all study procedures for the study. * Able to understand the study procedures, able to provide consent to participate in the study, and willing to authorize release of relevant protected health information by consenting to a HIPAA medical release form. Exclusion Criteria: * Known to be pregnant. * A medical condition which, in the opinion of the Investigator and/or Sponsor, should preclude enrollment in the study.

Related Trials